Brokerages Set Annexon, Inc. (NASDAQ:ANNX) PT at $15.80

Shares of Annexon, Inc. (NASDAQ:ANNX) have received an average rating of “Buy” from the six analysts that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock in the last year is $15.80.

Several brokerages have recently issued reports on ANNX. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Annexon in a report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Annexon in a research note on Tuesday, March 4th.

Institutional Trading of Annexon

Institutional investors have recently bought and sold shares of the stock. FMR LLC raised its stake in shares of Annexon by 3.2% in the third quarter. FMR LLC now owns 8,561,949 shares of the company’s stock valued at $50,687,000 after acquiring an additional 262,229 shares during the period. Point72 Asset Management L.P. lifted its stake in Annexon by 5.6% in the fourth quarter. Point72 Asset Management L.P. now owns 5,626,796 shares of the company’s stock worth $28,865,000 after purchasing an additional 299,798 shares during the last quarter. Vanguard Group Inc. lifted its stake in Annexon by 11.6% in the fourth quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company’s stock worth $28,456,000 after purchasing an additional 576,625 shares during the last quarter. State Street Corp grew its stake in shares of Annexon by 116.6% during the third quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after buying an additional 2,068,294 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of Annexon by 6.5% during the fourth quarter. Nuveen Asset Management LLC now owns 2,720,485 shares of the company’s stock valued at $13,956,000 after buying an additional 164,915 shares during the last quarter.

Annexon Stock Performance

Shares of NASDAQ ANNX opened at $2.50 on Thursday. The firm’s fifty day moving average is $3.34 and its two-hundred day moving average is $5.15. Annexon has a 52-week low of $2.30 and a 52-week high of $8.40. The company has a market cap of $274.28 million, a P/E ratio of -2.38 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last posted its earnings results on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). As a group, analysts forecast that Annexon will post -0.96 EPS for the current fiscal year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.